Nicotine Pouches: An FDA-Authorized Harm Reduction Product Whose Youth Use Is Still Climbing

The story in two numbers

The FDA authorized 20 ZYN nicotine pouch products through the premarket tobacco product application (PMTA) pathway and granted them a Modified Risk Tobacco Product (MRTP) claim — the first such authorization ever issued for a nicotine product. The agency’s reasoning: for adult smokers who switch completely, the risk profile is meaningfully lower than combustible cigarettes.

In the same period, NIDA-funded Monitoring the Future and the National Youth Tobacco Survey reported that 10th-grade nicotine pouch use rose from 1.9% (2023) to 3.4% (2024), and 12th-grade use jumped from 2.9% to 5.9% — roughly doubling. NIDA characterized year-over-year use among high-schoolers as up about 35%. Accidental ingestions by children under six surged 763% between 2020 and 2023.

The policy lens

The FDA’s MRTP authorization is a textbook application of population-level harm reduction: a product that delivers nicotine without combustion, sold to adults already nicotine-dependent, is plausibly a net public-health gain if it cannibalizes cigarette use. UCSF’s tobacco-control program filed formal opposition on the grounds that the modified-risk claim fails to account for non-smokers — particularly youth — who initiate nicotine use through pouches rather than transitioning from cigarettes. The National Center for Health Research filed a parallel comment. FDA opened a formal investigation of Zyn’s advertising and marketing practices in March 2026.

This is the structural tension in adult-tobacco harm reduction. The same product can be the right intervention for a 45-year-old smoker and the wrong one for a 16-year-old who has never smoked — and population-level policy has to land on a single answer.

The trends lens

Pouches resemble the early-2010s e-cigarette curve in shape, not in scale. Vaping use peaked at roughly 27% of high-schoolers in 2019 before regulatory action and product reformulation pulled the number down. Pouch use is still in the low single digits but is growing on a similar slope, and the marketing infrastructure is denser: Zyn’s parent company (Philip Morris International) has decades of regulatory and lobbying experience the early vape industry didn’t have. Industry voluntary commitments — no models under 35, no broadcast advertising, child-resistant packaging — track the same playbook used for cigarettes after the 1998 Master Settlement Agreement.

The science lens is genuinely uncertain. Long-term cardiovascular and oral-health data on nicotine-pouch use don’t yet exist; the products are too new. What is known: nicotine itself is a vasoconstrictor with documented effects on adolescent brain development, regardless of delivery vehicle.

Where the field disagrees

Tobacco-control researchers split on whether MRTP authorization sends the right signal at the right time. The FDA’s harm-reduction logic is internally consistent. The youth-uptake data is a real signal that the consistency does not survive contact with the actual market. Both can be true. The next eighteen months will tell us whether industry’s voluntary marketing restrictions hold and whether state-level age-of-sale enforcement catches up.

Resources

If you or someone you love is using nicotine pouches and wants to stop, 1-800-QUIT-NOW is a free national quitline; the Truth Initiative’s EX program is a free, free-to-use cessation tool that includes pouches in its scope. If you are in crisis or thinking about harming yourself, call or text 988.

Sources: FDA · Truth Initiative · AJMC · UCSF · NCHR